Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells

Hepatology

Volumn 30, Issue 1, 1999, Pages 300-307

  Yamamoto, Masato ^a,b   Hayashi, Norio ^a   Takehara, Tetsuo ^a   Ueda, Keiji ^a   Mita, Eiji ^a   Tatsumi, Tomohide ^a   Sasaki, Yutaka ^a   Kasahara, Akinori ^a,c   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KANSAI ROSAI HOSPITAL   (Japan)

^c OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; DOUBLE STRANDED DNA; HEPATITIS B CORE ANTIBODY; SINGLE STRANDED DNA; VIRUS RNA;

ANTIGEN BINDING; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA SEQUENCE; EXPRESSION VECTOR; GENE THERAPY; HEPATITIS B VIRUS; HEPATOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; VIRUS GENOME; VIRUS INHIBITION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CLONING, MOLECULAR; DNA, COMPLEMENTARY; GENOME, VIRAL; HEPATITIS B CORE ANTIGENS; HEPATITIS B VIRUS; HEPATOBLASTOMA; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LIVER NEOPLASMS; MICE; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0032999225     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300105     Document Type: Article

References (21)

1. Wright TL, Lau JYN. Clinical aspects of hepatitis B virus infection. Lancet 1993;342:1340-1344.
2. Lau JYN, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet 1993;342:1335-1340.
3. Hollinger FB. Hepatitis B virus. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996;2739-2807.
4. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakarishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver diseases. N Engl J Med 1993;328:1797-1801.
5. Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B. Ann Intern Med 1993;119:312-323.
6. Perrillo RP, Schiff ER, Davis GL, Bodenheimer HCJr, Lindsay K, Payne J, Dienstag JL, et al. A randomized control trial of interferon alfa-2b alone and after predonisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med 1990;323:295-301.
7. Krogsgaar K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, et al. The treatment of alpha interferon in chronic hepatitis B is independent of pre-treatment variables: results based on individual patients data from 10 clinical controlled trials. J Hepatol 1994;21:646-655.
8. Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997;113:1258-1263.
9. Lai CL, Ching CK, Tung AK, Li E, Young J, Hill J, Wong BC, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese. HEPATOLOGY 1997;25:241-244.
10. Bartholomew MM, Jansen RW, Jeffers LJ, Reddy LJ, Jonson LC, Bunzendahl H, Condreay LD, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-22.
11. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrel DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. HEPATOLOGY 1996;24:714-717.
12. Blum HE, Galun E, Von Weizsacker F, Wands J. Inhibition of hepatitis B virus by antisense oligonucleotides. Lancet 1991;337:1230.
13. Offensperger WB, Offensperger S, Walker E, Teubner K, Igloi G, Blum HE, Gerok W. In vivo inhibition of duck hepatitis B virus replication and gene expression by phosphorothioate modified antisense oligonucleotides. EMBO J 1993;12:1257-1262.
14. Carman W, Thomas H, Domingo E. Viral genetic variation: hepatitis B virus as a clinical example. Lancet 1993;341:349-353.
15. Von Weisäcker F, Wieland S, Köck J, Offensperger WB, Offensperger S, Moradpor D, Blum HE. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. HEPATOLOGY 1997;26:251-255.
16. Winter G, Milstein C. Man-made antibodies. Nature 1991;349:293-299.
17. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-554.
18. Bird RB, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee SM, Lee T, et al. Single-chain antigen-binding proteins. Science 1988;242:423-426.
19. Ganem D. Hepadnaviridae and their replication. In: Fields BN, Knipe DM, Howley PM, eds. Fields Virology. 3rd ed. Philadelphia: Lippincott-Raven, 1996;2703-2737.
20. Tsurimoto T, Fujiyama A, Matsubara K. Stable expression and replication of hepatitis B virus genome in an integrated state in a human hepatoma cell line transfected with the cloned viral DNA. Proc Natl Acad Sci U S A 1987;84:444-448.
21. Ueda K, Tsurimoto T, Nagahata T, Chisaka O, Matsubara K. An in vitro system for screening anti-hepatitis B virus drugs. Virology 1989;169:213-216.